topotecan has been researched along with mesna in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
Atay, AA; Demirkaya, E; Deveci, S; Kismet, E; Koseoglu, V | 1 |
Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; RavĂ , L | 1 |
Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM | 1 |
1 review(s) available for topotecan and mesna
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for topotecan and mesna
Article | Year |
---|---|
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Mucositis; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Topotecan; Transplantation, Autologous; Treatment Outcome | 2011 |
4 other study(ies) available for topotecan and mesna
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan | 2004 |
Panniculitis induced by a chemotherapy regimen consisting of topotecan and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Infant; Male; Mesna; Neoplasms, Germ Cell and Embryonal; Panniculitis; Topotecan | 2005 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |